Can a needle at the knee supercharge lung cancer immunotherapy?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 and ≤80 years at the time of written informed consent, of either sex; 2. Histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC) receiving neoadjuvant immunotherapy; 3. Undergoing standard neoadjuvant treatment with chemotherapy plus immunotherapy 4. ECOG performance status score of 0-2; 5. Life expectancy \>3 months; 6. At least one measurable target lesion per RECIST 1.1 criteria: 7. Tumor lesions with a long axis ≥10 mm on CT scan (slice thickness ≤5 mm); 8. Lymph node lesions with a short axis ≥10 mm on CT scan; 9. Previously irradiated or locally treated lesions may be designated as target lesions if documented tumor progression post-treatment. 10. Adequate major organ function within 14 days prior to randomization, defined by the following laboratory parameters without blood transfusions, growth factors, albumin, or blood products: 11. Hematological tests: Hemoglobin ≥80 g/L; Absolute neutrophil count \>1.5×10⁹/L; Platelet count ≥90×10⁹/L; 12. Biochemical tests: Total bilirubin ≤1.5×ULN (upper limit of normal); ALT/AST ≤2.5×ULN; Serum creatinine ≤1.5×ULN or creatinine clearance ≥50 mL/min (Cockcroft-Gault formula); 13. Coagulation tests: Prothrombin time (PT) and INR ≤1.5×ULN (unless on warfarin anticoagulation); 14. Cardiac evaluation: Left ventricular ejection fraction (LVEF) ≥50% by Doppler echocardiography. 15. Voluntary participation with signed informed consent, good compliance, and willingness of the patient and their family to cooperate with survival follow-up. Exclusion Criteria: 1. Pregnant participants; 2. Post-organ transplant patients; 3. Patients with uncontrolled diabetes mellitus, severe cardiac, central nervous system, psychiatric disorders, or coagulopathy; 4. Patients with severe malnutrition; 5. Patients with implanted cardiac pacemakers; 6. Patients with bleeding disorders; 7. Patients with a history of severe allergies or anaphylaxis; 8. Patients with skin infections, lesions, ulcers, or scars at the ST36 (Zusanli) acupoint site; 9. Patients with metal allergy, severe needle phobia, or intolerance to electroacupuncture therapy.